Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Six of Oxford University's distinguished scientists, and four from the Medical Sciences Division, have been elected as Fellows of the Royal Society for their outstanding contributions to science.

© OUI/Greg Smolonski

Image credit: OUI/Greg Smolonski

This year’s Fellows are:

Professor Neil Brockdorff FRS, Wellcome Trust Principal Research Fellow, Department of Biochemistry, University of Oxford.

Professor Vincenzo Cerundolo FMedSci FRS, Director, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford. The award recognises Professor Cerundolo’s world leading research on T cell immunology, particularly his discoveries on how peptides and lipids are processed and presented to T cells. This research has opened new therapeutic avenues. ‘I am extremely honoured and humbled to be receiving such an important recognition,’ said Professor Cerundolo, ‘I am certain that working in the exciting and vibrant environment of the MRC WIMM and being able to collaborate with so many outstanding colleagues has contributed enormously to this achievement.’ Find out more.

Professor Andrew King FMedSci FRS, Wellcome Trust Principal Research Fellow and Professor of Neurophysiology, Department of Physiology, Anatomy and Genetics, University of Oxford. Find out more.

Professor Dominic Kwiatkowski FMedSci FRS, Head of Parasites and Microbes Programme, Wellcome Sanger Institute and Professor of Genomics and Global Health, University of Oxford. Professor Kwiatkowski said: ‘I am honoured to be elected to the Fellowship of the Royal Society. It is a testimony to the amazing creativity and teamwork that is going on at Sanger and Oxford, and among all our partners in the MalariaGEN network. It is a great privilege to work with colleagues who are so committed to gaining a deep scientific understanding of malaria, not only as a fascinating biological problem, but also as a critical step in reducing the burden of disease in the poorest parts of the world.’

Professor Graham Richards CBE FRS, Chairman and Founder, Oxford Drug Design Ltd and Professor, Department of Chemistry, University of Oxford.

Professor Guy Wilkinson FRS, Professor of Physics, Department of Physics, University of Oxford.

Find out more (University of Oxford)

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.